{"filing": {"accession": "0001654954-26-003871", "cik": "0001133519", "ticker": "MCUJF", "company_name": "MEDICURE INC", "form_type": "20-F", "filing_type": "20-F", "filing_date": "2026-04-24", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1133519/000165495426003871/0001654954-26-003871-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1133519/000165495426003871/0001654954-26-003871-index.htm", "period_of_report": "2025-12-31"}, "html_url": "/api/filings/000165495426003871/stream", "exhibits": [], "sections": [], "tables": [{"table_index": 1, "table_type": "text", "caption": null, "header_text": "\u2610REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934"}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": "Large Accelerated Filer\u2610Non-Accelerated Filer\u2612"}, {"table_index": 7, "table_type": "financial", "caption": null, "header_text": "GENERAL1"}, {"table_index": 9, "table_type": "exhibit_index", "caption": null, "header_text": "ITEM 10. ADDITIONAL INFORMATION81"}, {"table_index": 12, "table_type": "text", "caption": null, "header_text": "\u00b7the Company\u2019s intention to sell and market its acute care cardiovascular drug, AGGRASTAT\u00ae, in the United States and its territories through its U.S. subsidiary, Medicure Pharma Inc.;"}, {"table_index": 14, "table_type": "financial", "caption": null, "header_text": "\u00b7the Company\u2019s intention to develop and implement clinical, regulatory and other plans to generate an increase in the value of AGGRASTAT\u00ae;"}, {"table_index": 15, "table_type": "financial", "caption": null, "header_text": "\u00b7general business and economic conditions;"}, {"table_index": 17, "table_type": "financial", "caption": null, "header_text": "\u00b7results of current and future clinical trials;"}, {"table_index": 20, "table_type": "text", "caption": null, "header_text": "(a)the success of the Company\u2019s research and development activities;"}, {"table_index": 25, "table_type": "text", "caption": null, "header_text": "\u00b7the Federal Anti-Kickback Law, which prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce ei"}, {"table_index": 31, "table_type": "text", "caption": null, "header_text": "\u00b7entering into agreements whereby other generic companies will begin to market an authorized generic, a generic equivalent of a branded product, at the same time generic competition initially enters t"}, {"table_index": 34, "table_type": "text", "caption": null, "header_text": "a)obtain and maintain U.S. and foreign patents, including defending those patents against adverse claims;"}, {"table_index": 43, "table_type": "text", "caption": null, "header_text": "\u00b7litigation or threat of litigation;"}, {"table_index": 55, "table_type": "text", "caption": null, "header_text": "Product CandidateTherapeutic focusStage of Development"}, {"table_index": 70, "table_type": "text", "caption": null, "header_text": "Product CandidateTherapeutic focusStage of Development"}, {"table_index": 72, "table_type": "text", "caption": null, "header_text": "Patent NumberIssue DateTitle"}, {"table_index": 77, "table_type": "financial", "caption": null, "header_text": "\u00b7Note 3(i): The measurement and useful lives of intangible assets"}, {"table_index": 90, "table_type": "text", "caption": null, "header_text": "\u00b7the accounting principles used by the Company to prepare its financial statements, and the ability to assess the general application of those principles in connection with estimates, accruals and res"}, {"table_index": 98, "table_type": "text", "caption": null, "header_text": "\u00b7Any management or human resources function;"}, {"table_index": 109, "table_type": "text", "caption": null, "header_text": "Title of ClassIdentity of Person or GroupAmount OwnedPercentage of Class"}, {"table_index": 112, "table_type": "text", "caption": null, "header_text": "Name of PersonNumber ofShares Subjectto IssuanceExercisePrice perShareExpiry Date"}, {"table_index": 114, "table_type": "text", "caption": null, "header_text": "Title of ClassIdentity of Person or GroupAmount OwnedPercentage of Class"}, {"table_index": 117, "table_type": "financial", "caption": null, "header_text": "(1)enter into any transactions which are material to the Company or a related party or any transactions unusual in their nature or conditions involving goods, services or tangible or intangible assets"}, {"table_index": 118, "table_type": "text", "caption": null, "header_text": "(a)enterprises directly or indirectly through one or more intermediaries, controlling or controlled by or under common control with the Company;"}, {"table_index": 122, "table_type": "text", "caption": null, "header_text": "i)borrow money upon the credit of the Company;"}, {"table_index": 125, "table_type": "text", "caption": null, "header_text": "i)the judgment was rendered in a U.S. court that had no jurisdiction according to applicable laws in Canada;"}, {"table_index": 128, "table_type": "text", "caption": null, "header_text": "a)the acquisition of voting shares or other voting interests by any person in the ordinary course of that person\u2019s business as a trader or dealer in securities;"}, {"table_index": 141, "table_type": "financial", "caption": null, "header_text": "1.pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;"}, {"table_index": 144, "table_type": "text", "caption": null, "header_text": "(a) Audit fees20252024"}, {"table_index": 148, "table_type": "financial", "caption": null, "header_text": "1.Consolidated Statements of Financial Position;"}, {"table_index": 151, "table_type": "text", "caption": null, "header_text": "/s/ Albert Friesen/s/ Haaris Uddin"}, {"table_index": 154, "table_type": "financial", "caption": null, "header_text": "Assessment of accrual for chargebacks"}, {"table_index": 156, "table_type": "financial", "caption": null, "header_text": "Valuation of goodwill relating to the Retail and Mail Order Pharmacy cash-generating unit [\u201cCGU\u201d]"}, {"table_index": 157, "table_type": "financial", "caption": null, "header_text": "Valuation of intangible assets in acquisition of Gateway and West Olympia pharmacies"}, {"table_index": 160, "table_type": "financial", "caption": null, "header_text": "As at December 31Note20252024"}, {"table_index": 161, "table_type": "text", "caption": null, "header_text": "\u201cDr. Albert D. Friesen\u201d\u201cMr. Brent Fawkes\u201d"}, {"table_index": 164, "table_type": "financial", "caption": null, "header_text": "For the year ended December 31Note202520242023"}, {"table_index": 174, "table_type": "financial", "caption": null, "header_text": "For the year ended December 31Note202520242023"}, {"table_index": 180, "table_type": "financial", "caption": null, "header_text": "\u00b7Note 3(i): The measurement and useful lives of intangible assets"}, {"table_index": 191, "table_type": "financial", "caption": null, "header_text": "AssetBasisRate"}, {"table_index": 206, "table_type": "financial", "caption": null, "header_text": "Net assets acquired"}, {"table_index": 209, "table_type": "financial", "caption": null, "header_text": "Net assets acquired"}, {"table_index": 212, "table_type": "text", "caption": null, "header_text": "As at December 3120252024"}, {"table_index": 213, "table_type": "text", "caption": null, "header_text": "As at December 3120252024"}, {"table_index": 216, "table_type": "financial", "caption": null, "header_text": "CostComputersandequipmentLeaseholdimprovementsRight of useassetsTotal"}, {"table_index": 219, "table_type": "financial", "caption": null, "header_text": "CostLicensesPatents and drug approvalsBrand names and trademarksCustomer listSoftware and technologyTotal"}, {"table_index": 222, "table_type": "text", "caption": null, "header_text": "Retail and Mail Order Pharmacy"}, {"table_index": 225, "table_type": "text", "caption": null, "header_text": "Incremental borrowing rate %Maturity20252024"}, {"table_index": 228, "table_type": "text", "caption": null, "header_text": "Number of common sharesAmount"}, {"table_index": 230, "table_type": "text", "caption": null, "header_text": "Year ended December 31, 2024OptionsWeightedaverageexerciseprice"}, {"table_index": 231, "table_type": "text", "caption": null, "header_text": "Year ended December 3120242023"}, {"table_index": 234, "table_type": "text", "caption": null, "header_text": "Range ofexercise pricesNumberoutstandingWeightedaverageremainingcontractual lifeOptions outstandingweighted averageexercise priceNumberexercisable"}, {"table_index": 235, "table_type": "text", "caption": null, "header_text": "Years ended December 31:2025"}, {"table_index": 236, "table_type": "text", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 237, "table_type": "text", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 240, "table_type": "text", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 241, "table_type": "financial", "caption": null, "header_text": "As at December 3120252024"}, {"table_index": 242, "table_type": "financial", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 243, "table_type": "financial", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 246, "table_type": "text", "caption": null, "header_text": "2037$1,820"}, {"table_index": 247, "table_type": "text", "caption": null, "header_text": "2026$1,469"}, {"table_index": 248, "table_type": "financial", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 249, "table_type": "text", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 252, "table_type": "text", "caption": null, "header_text": "2026$2,625"}, {"table_index": 257, "table_type": "text", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 262, "table_type": "financial", "caption": null, "header_text": "Year ended December 31202520242023"}, {"table_index": 263, "table_type": "financial", "caption": null, "header_text": "\u00b7Level 1 \u2013 Quoted prices (unadjusted) in active markets for identical assets or liabilities;"}, {"table_index": 264, "table_type": "financial", "caption": null, "header_text": "Level 1Level 2Level 3"}, {"table_index": 267, "table_type": "financial", "caption": null, "header_text": "As at December 31(Expressed in U.S. Dollars)20252024"}, {"table_index": 272, "table_type": "text", "caption": null, "header_text": "As at December 3120252024"}, {"table_index": 275, "table_type": "financial", "caption": null, "header_text": "For the year ended December 31, 2025Marketing and Distribution of Commercial ProductsRetail and Mail Order PharmacyTotal"}, {"table_index": 276, "table_type": "financial", "caption": null, "header_text": "For the year ended December 31, 2024Marketing and Distribution of Commercial ProductsRetail and Mail Order PharmacyTotal"}, {"table_index": 278, "table_type": "exhibit_index", "caption": null, "header_text": "NumberExhibit"}, {"table_index": 280, "table_type": "text", "caption": null, "header_text": "4.10Amendment to Employment Agreement dated April 5, 2005 between A.D. Friesen Enterprises Ltd. and the Company [5]"}, {"table_index": 282, "table_type": "text", "caption": null, "header_text": "12.2Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *"}, {"table_index": 283, "table_type": "text", "caption": null, "header_text": "*Filed herewith"}], "exhibits_pending": true, "cdn_html": true, "response_time_ms": 30}